News

Gilead Sciences (GILD) reached $134.32 at the closing of the latest trading day, reflecting a +2.91% change compared to its last close.

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Atea Pharmaceuticals (AVIR) said Tuesday a pivotal phase 3 trial of its experimental combination the

Kalshi sees drug development predictions as a way to improve R&D transparency. Critics say they could create financial incentives around research and undermine public trust.

Most biotech investors treat FBT and IBB as two names for the same trade, but the structural differences buried in their index methodologies have produced shockingly different outcomes depending on where the market's momentum actually lives.

Gilead Sciences (GILD) closed the most recent trading day at $129.31, moving 1.18% from the previous trading session.

GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.

A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.

Gilead Sciences plans to present new HIV research data at AIDS 2026. The presentations will include long term efficacy and safety results from lenacapavir. Gilead will also share data on a novel HIV treatment regimen developed with Merck. For investors following Gilead Sciences, NasdaqGS:GILD, the announcement connects directly to how the market views the company’s HIV portfolio. The stock recently closed at $130.28, with a return of 7.1% year to date and 21.3% over the past year. Over a 5...

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.

Gilead Sciences will release its second-quarter earnings soon, and analysts anticipate a triple-digit profit dip.

Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.

In the most recent trading session, Gilead Sciences (GILD) closed at $134.28, indicating a -1.48% shift from the previous trading day.

Gilead stock is closely tied to its HIV treatments. But with Biktarvy's patent expirations looming, can the giant survive?

Prediction market Kalshi is allowing users to bet on the outcomes of clinical trials and U.S. Food and Drug Adminis...

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

(Bloomberg) -- Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI CompanionCIA Says AI Drones Give Russian Troops Only 30 Minutes to LiveBeckham’s IM8 Gets $1 Billion From General Catalyst for GrowthOnePlus

Both Pfizer and Gilead Sciences just flashed the same ominous technical warning while trading below analyst fair value, but the reasons behind each selloff tell very different stories about which one actually deserves a second look.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Gilead Sciences (NASDAQ:GILD) and the best and worst performers in the therapeutics industry.

For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.

Gilead's expansion beyond HIV therapies will surprise many investors.

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day.

You don't need to predict a recession to prepare your portfolio. These two stocks can help.

Gilead Sciences stock has delivered a strong 5 year run, yet current valuation checks paint a more mixed picture. The overall score sits between clearly cheap and clearly expensive, while recent oncology and HIV news keeps expectations elevated. Over the past 5 years, Gilead Sciences has returned about 140.0%, which puts more pressure on today’s valuation to be backed by durable cash flows rather than just sentiment. Regulatory approvals and positive momentum for Trodelvy and Yeztugo can...

Gilead Sciences (NasdaqGS:GILD) received FDA approval for Trodelvy in first line treatment of advanced triple negative breast cancer. European regulators also approved Trodelvy in the same setting for eligible patients. The company entered a partnership with BBG Advanced Therapies to deploy a mobile center offering Kite CAR T cell therapies across Texas. These updates place oncology and cell therapy firmly at the center of Gilead Sciences' story, alongside its established presence in...

Gilead Sciences (GILD) has just been removed from several Russell growth oriented indexes. This is a technical shift that can affect how some funds hold the stock and how investors view its role in portfolios. See our latest analysis for Gilead Sciences. Recent news around index removals and drug approvals has come alongside a 7.82% 7 day share price return and an 11.69% year to date share price gain for Gilead Sciences. Its 1 year total shareholder return of 23.06% and 5 year total...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable Cheap Stocks to Buy Right Now. On June 30, Morgan Stanley kept its Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) and maintained its price target of $168. The research firm’s positive view is based on a number of factors, including the company’s growth outlook […]

Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th

On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”